Cite
HARVARD Citation
Gottfried, M. et al. (n.d.). 484PActivity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials. Annals of oncology. p. . [Online].